Fig 3.tif (1.32 MB)

Upregulation of IGF-I and IGF-IR in HBV-HCC cell lines with inflamed-CM treatment.

figure

posted on 2016-02-26, 08:27 authored by Te-Sheng Chang, Chi-Long Chen, Yu-Chih Wu, Jun-Jen Liu, Yung Che Kuo, Kam-Fai Lee, Sin-Yi Lin, Sey-En Lin, Shui-Yi Tung, Liang-Mou Kuo, Ying-Huang Tsai, Yen-Hua Huang

mRNA levels of IGF-I and IGF-IR in human HCC cell lines of HepG2.2.15, Hep3B, PLC5 (HBV⁺HBsAg⁺), HA22T (HBV⁺HBsAg⁻), HepG2, and Huh7 (HBV⁻HBsAg⁻) with inflamed-CM treatment for 7 days (by quantitative real-time RT-PCR). The dashed line indicates the gene expression in HCC cells without inflamed-CM treatment (multiple of expression = 1, control group). (B) IGF-IR levels in HCC cells with and without inflamed-CM treatment (by Western blotting). (C) Effect of inflamed-CM on the activation of IGF-IR/Akt signaling in HBV⁺HBsAg⁺ HepG2.2.15 and Hep3B is shown. (D) Effect of IGF-IR phosphorylation inhibitor PPP on inflamed-CM-induced IGF-IR/Akt signaling activation is shown. Effect of PPP (1 μM) on inflamed-CM-induced mRNA levels of OCT4 (E) and NANOG (F) in HepG2.2.15 and Hep3B cells is shown. **P < .01, ***P < .001, by t-test.